DANIEL ERNESTO
CASTELLANO GAUNA

Profesor asociado de Ciencias de la Salud

Foto de DANIEL ERNESTO

Foto de Ovidio

Ovidio
Fernández Calvo

Ovidio Fernández Calvo-rekin lankidetzan egindako argitalpenak (5)

2023

A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide
Prostate, Vol. 83, Núm. 4, pp. 376-384

2022

Clinical Factors Associated With Long-Term Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-World AXILONG Study
Clinical Genitourinary Cancer, Vol. 20, Núm. 1, pp. 25-34
Corrigendum to “589P Dynamics of peripheral blood immune profiling associated with tumour progression in metastatic castration resistant prostate cancer (mCRPC)”: [Annals of Oncology 32 suppl. 5 (2021) S637-S638] (Annals of Oncology (2021) 32 suppl. 5(S637-S638) (S0923753421033317), (10.1016/j.annonc.2021.08.1102))
Annals of Oncology

2017

Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: A multi-institution correlative biomarker study
Annals of Oncology, Vol. 28, Núm. 7, pp. 1-9
Weekly cabazitaxel plus prednisone is effective and less toxic for ‘unfit’ metastatic castration-resistant prostate cancer: Phase II Spanish Oncology Genitourinary Group (SOGUG) trial
European Journal of Cancer, Vol. 87, pp. 30-37